Metropolis Healthcare stock soars over 2% on reporting 23% YoY revenue growth in Q2; check business update

At around 2:45 pm, the stock was trading 1.92% higher at ₹2,112.8 per equity share.

This comes after the diagnostic chain shared its Q2 business update on Monday, stating that it has delivered a strong 23% year-on-year (YoY) revenue growth at the consolidated level, driven by robust momentum in preventive health check-ups such as TruHealth and wellness offerings.

During the reporting quarter, the TruHealth Wellness and Specialty segments recorded growth of approximately 25% and 36% YoY, respectively.

Its revenue from business-to-client (B2C) surged about 16% YoY, while its business-to-business (B2B) revenue growth stood at approximately 34% YoY, with B2B contributing more to its core diagnostics business.

The top-line growth includes revenues from core diagnostics, scientific pathology (Scientific), Agra, and Dr. Ahuja’s Pathology & Imaging Center (DAPIC) in Dehradun.

Post acquisition, its core diagnostics business progressed from a breakeven position in the fourth quarter of FY25 to a low single-digit positive margin in the June quarter of FY26, and stood at a high single-digit margin in the second quarter of FY26, driven by ongoing improvements in operational efficiency, operating leverage, and synergies.

Additionally, DAPIC and Scientific consistently outperformed the company’s average margin, it added.

At the consolidated level, the firm’s EBITDA (earnings before interest, tax, depreciation and amortisation) margin remained strong, bolstered by operating leverage in the organic business and integration synergies at core diagnostics, which contributed to the overall margin growth QoQ.

During the September quarter of FY26, the company was debt-free and had a net cash surplus of about ₹55 crore.

While the incidence of seasonal illnesses such as Chikungunya, malaria, dengue, and viral fever was lower than last year, "our performance underscores the strength of our diversified portfolio, resilience against seasonal headwinds, and alignment with the growing customer preference for proactive health and well-being," the regulatory filing said.

The company also completed the acquisition of Kolhapur’s Ambika Pathology Laboratory through a business transfer agreement, effective September 18, 2025.